Key Takeaways
- CDMO delivered 34% YoY growth in Q2, extending the streak to 15 consecutive quarters of record revenue, with management crediting team execution over API price movements.
- Trade generics is in a deliberate reset: revenue fell to ₹36 crores in Q2 after codeine-based products were pulled, and the company is rebuilding the portfolio with a broader, non-codeine base.
- EU GMP certification for injectables at Plants 4 and 5 is a milestone that unlocks a higher-margin export mix, though product-wise approvals and revenue contribution remain on the regulator's timeline.
- Margins are structurally improving: EBITDA margin ex-ESOP reached 13.7% in Q2 and H1, up from the historical 11–12% band, with further opportunity tied to mix and an opex reduction project.
- What to watch next quarter: whether trade generics growth resumes toward pre-codeine levels in FY28 as management aspires, the pace of injectables capacity fill post-EU GMP, and any inorganic move into a new dosage form.
CDMO: The Growth Engine
- Broad-based momentum: Q2 CDMO revenue of ₹215 crores came from more business in existing products, new products with existing customers, and new products with new customers, with no one-off or concentration in any single product, customer, or therapeutic category.
- Share gain, not claimed as permanent: Management attributes the 34% YoY growth to positive customer response, better negotiation by the business development team, and increased customer confidence, but frames it as higher share in these two quarters rather than a structural shift.
- API price volatility is not the story: The company works with 700–800 APIs and delivered strong growth even when API prices were declining; management explicitly credits team execution, not input-cost tailwinds.
- Quality as a self-reinforcing moat: Audits by large multinational and Indian customers drive continuous quality improvement and reduce regulatory exposure risk, a dynamic management calls "very self-reinforcing."
- Regulatory tightening helps the organized: Schedule M implementation has intensified, with many plants shuttered and the regulator conducting random testing; tougher standards should benefit compliant players like Windlas.
Hitesh Windlass: "My instinct is to say that this is a credit to the team rather than credit to API prices."
Trade Generics: Reshaping After the Codeine Shock
- The codeine event: Codeine-based formulations, among the biggest brands in Indian pharma, were pulled back by brand owners, and Windlas lost that business alongside other large trade generics players.
- Portfolio rebuild underway: The company is filling the gap with broader SKUs including non-codeine cough syrups and other products, while extending liquid capacity to CDMO customers to absorb the lost volume.
- Margin profile is attractive: On a material margin basis, trade generics is a higher-margin business than CDMO, so recovery matters for the blended margin trajectory.
- FY28 aspiration: Management aims for trade generics growth to resume to pre-codeine levels in FY28, and potentially more, with the long-term growth outlook unchanged.
- No timeline commitment: Management declined to say when trade generics can return to the ₹200 crores base it was previously targeting, calling the rebuild a step-by-step effort.
Hitesh Windlass: "Does codeine define trade generics, or is the requirement for medicines and the gap of access to quality medicines remain fundamentally there, regardless of one particular SKU being impacted?"
Exports & EU GMP: The Injectables Opportunity
- EU GMP certification achieved: Plants 4 and 5, the injectable facility, received EU GMP certification during Q2, on the first attempt, a milestone management calls a strong validation of quality systems.
- Revenue is gated by product approvals: Filings have been submitted, but product-wise approvals follow plant approval and depend on the reviewing authority, which is not time-bound; management has internal expectations but will not share dates.
- Business model will be hybrid: EU injectables revenue will come from a mix of CDMO work and tying up with marketing companies using Windlas's own marketing authorizations.
- Segment potential is material: Management believes this can become a big segment two to three years down the line and is committed to growing it.
- Exports already contributing: Q2 exports grew 26% YoY to ₹12 crores, H1 grew 46% to ₹23 crores, as dossier investments, product registrations, and site approvals began converting into commercial supplies.
Hitesh Windlass: "I can sort of state that we are executing towards that goal, and I'm very glad to share that we have been successful in our first attempt with EU GMP for injectables."
Capacity, Capex & Capital Allocation
- Plant 6 live: Commercialized on September 28, 2026, adding 20 crore tablets/capsules of oral solids capacity, built phase-wise to avoid underutilization.
- Existing ceiling: Current facilities can serve up to ₹1,100 crores at the company level, with scope for up to 10% improvement through consistent efforts; new capacity will be triggered only when peak levels are approached.
- Opex reduction project: A capex investment of ₹25–30 crores is planned, expected to deliver operational expenditure savings of a similar magnitude; details and timeline are still to come.
- Capital allocation philosophy, in order: (1) an acquisition they like, (2) capex for core business dosage forms, (3) internally building a new dosage form if no inorganic deal materializes, (4) buyback when the market price is much lower than intrinsic value, (5) continuing the dividend policy, (6) rewarding long-term employees.
- Inorganic prudence: Management has avoided rushing into acquisitions and "owning somebody else's problem," and will continue to be careful; no deal is in final stages.
Komal Gupta: "Because we have liquidity, we want to put the money somewhere is not how we think about it. How we think about is having enough, number one. Number two is in terms of strategy of how to spend the money is very clear."
Margins: The Step-Up and What Comes Next
- Structural improvement visible: EBITDA margin ex-ESOP reached 13.7% in Q2 and H1 FY27, up from the historical 11–12% range, as operational efficiency converted into reported numbers.
- Mix is a lever: Trade generics carries higher material margins than CDMO, injectables exports have much higher margins than domestic, and domestic injectables is also lucrative compared to CDMO, so the recovery of trade generics and ramp of injectables both pull margins up.
- Further opportunity exists: Management sees positive growth possibility in EBITDA percent and states that even maintaining the post-ESOP percentage is an improvement; better execution and mix can deliver more.
- Opex project adds another layer: The ₹25–30 crore efficiency investment, if it delivers as planned, would provide an additional margin tailwind in coming quarters.
Komal Gupta: "Consistency is not the most exciting word in business, but it is the one our customers and shareholders value the most."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Trade generics recovery | Growth to resume to pre-codeine event numbers, potentially more | FY28 (aspiration) |
| Capacity ceiling | Existing facilities can serve up to ₹1,100 crores company-level, with up to 10% improvement possible | Current state |
| New oral solids capacity | Phase-wise build starts when existing facilities approach peak | Trigger-based, no date |
| Opex reduction project | Capex of ₹25–30 crores, expected to reduce opex by similar magnitude | "Coming quarters" (vague) |
| EU injectables revenue | Product-wise approvals follow plant approval; internal expectations exist but not shared | Dependent on regulator |
| New dosage form | Actively looking for acquisition; if none finalized, may build internally; nothing initiated yet | No timeline |
| Capital allocation | Priority order: acquisition, core capex, internal new dosage form, buyback, dividend, employee rewards | Ongoing philosophy |
| Buyback | Completed ₹47 crores without promoter participation; future buybacks if market price is much lower than intrinsic value | Condition-based |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹264 cr, +19% YoY |
| H1 FY27 revenue | ₹512 cr, +18% YoY; first time crossing ₹500 cr half-yearly |
| Generic formulation CDMO revenue | ₹215 cr, +34% YoY |
| Trade generics & institutional revenue | ₹36 cr |
| Exports revenue | ₹12 cr, +26% YoY |
| EBITDA (excl. ESOP) | ₹36 cr, 13.7% margin; improved from historical 11–12% |
| PAT (excl. ESOP) | ₹25 cr, 9.5% margin |
| Reported EBITDA | ₹29 cr |
| Reported PAT | ₹18 cr |
| H1 FY27 EPS | ₹17.21, highest-ever |
| ROCE | 28% |
| ROE | 24% |
| Net liquidity (H1 FY27 close) | ₹223 cr |
| Indian pharma market volume growth | 2.5% during the quarter |
| Plant 6 commercialization | September 28, 2026; costs flow to Q3 |
| Opex reduction project capex planned | ₹25–30 cr |